Analysts on Wall Street project that Thermo Fisher Scientific (TMO) will announce quarterly earnings of $5.71 per share in its forthcoming report, representing an increase of 6.5% year over year. Revenues are projected to reach $11.68 billion, increasing 7.6% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenues- Laboratory Products and Biopharma Services' stands at $6.46 billion. The estimate indicates a change of +7.7% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Specialty Diagnostics' reaching $1.17 billion. The estimate suggests a change of +2.8% year over year.
According to the collective judgment of analysts, 'Revenues- Life Sciences Solutions' should come in at $2.74 billion. The estimate indicates a year-over-year change of +9.6%.
The consensus among analysts is that 'Revenues- Analytical Instruments' will reach $1.81 billion. The estimate indicates a year-over-year change of +4.7%.
View all Key Company Metrics for Thermo Fisher here>>>Shares of Thermo Fisher have experienced a change of +14.6% in the past month compared to the +0.6% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), TMO is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).